Lymphocyte Function-Associated Antigen-1 (LFA-1)

An integrin heterodimer widely expressed on cells of hematopoietic origin. CD11A ANTIGEN comprises the alpha chain and the CD18 antigen (ANTIGENS, CD18) the beta chain. Lymphocyte function-associated antigen-1 is a major receptor of T-CELLS; B-CELLS; and GRANULOCYTES. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by NATURAL KILLER CELLS and granulocytes. Intracellular adhesion molecule-1 has been defined as a ligand for lymphocyte function-associated antigen-1.

Also Known As:

Networked: 669 relevant articles (15 outcomes, 61 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ballantyne, Christie M: 7 articles (04/2008 - 01/2002)
2.	Tremblay, Michel J: 6 articles (11/2009 - 02/2002)
3.	Ley, Klaus: 5 articles (08/2012 - 01/2002)
4.	Thorlacius, Henrik: 5 articles (05/2011 - 12/2002)
5.	Siahaan, Teruna J: 5 articles (02/2010 - 03/2002)
6.	Kachlany, Scott C: 4 articles (03/2015 - 06/2010)
7.	Hogg, Nancy: 4 articles (04/2013 - 07/2003)
8.	Leite, F: 4 articles (02/2005 - 08/2002)
9.	Czuprynski, C J: 4 articles (02/2005 - 08/2002)
10.	Atapattu, D: 4 articles (02/2005 - 08/2002)

Related Diseases

1.	Inflammation 10/15/1994 - "An Ab against rabbit LFA-1 effectively inhibited the adhesion of rabbit polymorphonuclear leukocytes to rabbit endothelial cells in culture and was also effective in blocking cell recruitment to the peritoneum and vascular leakage at dermal sites of inflammation. " 10/19/2001 - "These results demonstrate the efficacy of small molecule inhibitors of LFA-1 in preclinical models of inflammation dependent on human or non-human primate LFA-1." 09/30/2015 - "DEL-1 (developmental endothelial locus-1) is an endothelial cell-secreted protein that regulates LFA-1 (lymphocyte function-associated antigen-1) integrin-dependent leukocyte recruitment and inflammation in various tissues. " 01/01/2014 - "TNF-α upregulates intercellular adhesion molecule (ICAM)-1 expression on the RPE, which allows lymphocyte function-associated antigen-1 (LFA-1) to bind on leukocytes that contribute to leukocyte adhesion at sites of inflammation. " 05/01/2013 - "Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)."
2.	Infection 10/01/2002 - "Quantitative transmission electron microscopy studies revealed that macrophage adhesion was accompanied by increases in levels of LFA-1 and its counter receptor (ICAM-1), decreases in surface levels of the phagocytic receptors CR3, CR4 and FcgammaRII, and an increase in major histocompatibility complex Class II (MHC-II) molecules at 72 h post-infection. " 03/24/2011 - "Through its control of high-affinity LFA-1, the LFA-1/Lck/ZAP-70 complex is in position to initiate the rapid adhesion strengthening and migration necessary for T-lymphocyte responses when stimulated vasculature is encountered at sites of infection or injury." 10/01/2010 - "In addition, PbA infection-induced LFA-1 expression in CD8(+) T cells was suppressed in PKCθ-deficient T cells, suggesting a diminished ability to adhere to endothelial cells and sequester in brain microvasculature, which may explain the decrease in neurological symptoms. " 11/01/2009 - "LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20." 04/15/2006 - "The LFA-1 adhesion molecule is required for protective immunity during pulmonary Mycobacterium tuberculosis infection."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2003 - "We present a review of the literature concerning treatment of psoriasis with humanized monoclonal antibody (hu 1124, efaluzimab, Xanelin) against the CD11a component of lymphocyte-function-associated antigen-1 (LFA-1). " 09/01/1992 - "In normal skin positive staining for CD18 was not observed, whereas in psoriasis both CD1a+ and CD1a- DCs expressed beta 2-integrins, LFA-1 (CD11a/CD18), and gp 150/95 (CD11c/CD18). " 05/27/2012 - "As an antagonist against human LFA-1 exists and has been used clinically to treat psoriasis, these findings have significant translational potential for future clinical transplant trials." 10/01/2011 - "Targeting LFA-1 and preventing interaction with ICAM-1 has proven an effective strategy for treating psoriasis. " 01/01/2007 - "In a pilot study 6 psoriasis patients were treated over 12 weeks with efalizumab targeting the CD11a subunit of LFA-1. "
4.	Autoimmune Diseases (Autoimmune Disease) 08/01/2004 - "These studies identify LFA-1 as a key contributor in the pathogenesis of autoimmune disease in this model, and further suggest that therapeutic strategies targeting this adhesion molecule may be beneficial for the treatment of SLE." 01/20/2012 - "CD11a, a subunit of the β2-integrin LFA-1 (CD11a/CD18) with costimulatory functions, is overexpressed due to hypomethylation of its promoter regulatory elements in CD4+ T cells from patients with many autoimmune diseases. " 10/01/2008 - "A series of meta-substituted anilines were designed and synthesized to inhibit the interaction of LFA-1 with ICAM for the treatment of autoimmune disease. " 08/01/2004 - "Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease." 03/01/2003 - "This review describes the role of modulation of intracellular adhesion molecule-1 (ICAM-1)/leukocyte function-associated antigen-1 (LFA-1) interaction in controlling autoimmune diseases or inducing immunotolerance. "
5.	Multiple Sclerosis 03/01/2010 - "Studies in EAE, the animal model for multiple sclerosis, show differential requirements for beta(2)-integrins in this disease model, ranging from critical in the case of LFA-1 (CD11a/CD18) to unimportant in the case of CD11d/CD18. " 10/01/1996 - "To identify potential molecular substrates for leukocyte trafficking and activation in multiple sclerosis (MS) brain, we determined the immunocytochemical distribution of the beta, integrin lymphocyte-function-associated antigen-1 (LFA-1) and its major ligands, intercellular adhesion molecule (ICAM)-1, ICAM-2, and ICAM-3 in MS tissue. " 09/01/1995 - "These findings suggest that LFA-1 and ICAM-1 are critically involved in the development of EAE and that the administration together of mAbs against adhesion molecules including LFA-1 and ICAM-1 might provide a new immunotherapeutic approach for the treatment of multiple sclerosis." 10/01/1996 - "Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions." 08/01/1996 - "In conclusion, intrathecal administration of antibodies against LFA-1 and ICAM-1 may be useful for the treatment of human demyelinating diseases, such as multiple sclerosis."

Related Drugs and Biologics

1.	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
2.	Monoclonal Antibodies
3.	Lymphocyte Function-Associated Antigen-1 (LFA-1)
4.	Integrin alpha4beta1 (VLA-4)
5.	Antibodies
6.	Membrane Glycoproteins (Membrane Glycoprotein)
7.	leukotoxin
8.	Bacterial Proteins (Bacterial Protein)
9.	Antigens
10.	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Transplants (Transplant)
4.	Homologous Transplantation (Allograft)
5.	Ligation